Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

259.93
-1.6600-0.63%
Post-market: 260.460.5300+0.20%19:54 EDT
Volume:3.89M
Turnover:1.01B
Market Cap:459.40B
PE:73.43
High:262.32
Open:260.51
Low:259.00
Close:261.59
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.03
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.63%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.40
PE(LYR):110.14

Loading ...

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Citi Keeps Their Hold Rating on AbbVie (ABBV)

TIPRANKS
·
Sep 29

AbbVie price target raised to $289 from $282 at BofA

TIPRANKS
·
Sep 29

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Quantum-Si (QSI)

TIPRANKS
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

TIPRANKS
·
Sep 28

US FDA Approves AbbVie's Drug for Parkinson's Disease

Reuters
·
Sep 26

US FDA - Approves Juvmo (Tavapadon) for Parkinson’s Disease in Adults on Sept 25, 2026

THOMSON REUTERS
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

MT Newswires Live
·
Sep 25

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24